MAM
Myntra brings kids wear brand, OshKosh B’Gosh® to India in partnership with Tablez
Bengaluru: Myntra announces the launch of OshKosh B’Gosh one of the most-recognized children’s clothing brands in the United States. Their signature style is rooted in denim, an optimistic color palette and an artful attention to detail. It is clothing that nods to the brand’s roots while moving forward with the perfect balance of quality, value, fashion and kid-friendly style. Along with iconic products like the World’s Best Overalls and Heritage Logo Hoodies – OshKosh B’Gosh® creates clothing that lets kids be kids.
OshKosh B’Gosh® is being launched for the first time in India and will be available online on Myntra through Tablez, the leading organized retail group, the official partner of Oshkosh B’Gosh® in India.
Myntra has over 65000 options from over 400 kids wear brands and is the go-to destination for branded apparel products. With a good mix of large global brands and small domestic boutiques, Myntra’s range offers both, value for money and quality to shoppers in India. According to industry reports, the kids fashion market in India stands at $7 billion at present and is expected to reach $13 billion by 2022, with the branded segment gaining fast traction among shoppers.
Speaking on the launch, Amar Nagaram, Head – Myntra Jabong said, “We are delighted to bring OshKosh B’Gosh®, one of the United States leading kids wear brands to our customers in India in partnership with Tablez. We are committed to creating a fashion destination for kids and are focused on building the infant and footwear portfolio, while enhancing the overall catalogue for kids and pre-teens. With our large user base and wide reach, Myntra offers the perfect channel for OshKosh B’Gosh® to scale swiftly, in this market while also helping us solidify our position as the leading destination for kids wear in the country.”
Speaking on the association, Adeeb Ahamed, Managing Director, Tablez, said, “We are very excited to bring OshKosh B’Gosh® to India and partner with Myntra, to offer the brand on its well reached platform. OshKosh B’Gosh® is a time-tested kids wear brand from the USA, offering contemporary fashion with a wide variety of styles and trends. We believe that it has great potential to become one of the leading brands in the kids wear segment in India. Being a pioneer in the e-commerce market and its extensive reach, Myntra is the perfect partner that will enable OshKosh B’Gosh® to reach a large expanse of the fashion-conscious consumers across the country.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
